Chemical structure of GSK852 BET BD2 inhibitor

>1000x BD2-selective BET bromodomain inh.

orally available in dog

rational design from prior lead

Journal of Medicinal Chemistry

GlaxoSmithKline, Stevenage, UK

The GSK BET BD2 inhibitor, GSK852, is one of a series of BD2-targeting compounds published last month by GSK (see a fragment-based approach here, a DEL screening approach here, and a pincolinamide…


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.